Staging and prognostic factors in nonseminomatous testicular cancer
- PMID: 1663942
Staging and prognostic factors in nonseminomatous testicular cancer
Abstract
Staging of nonseminomatous testicular cancers, as with other tumors, renders important prognostic information and is necessary for making appropriate treatment recommendations. There is no universally accepted staging system for testis cancer, however. Despite the lack of uniformity, most of the staging systems in use today are capable of segregating patients into a "good-risk" or "poor-risk" category. The former group experiences cure less frequently and are appropriate candidates for investigational treatment. Tumor bulk is the most important prognostic factor in virtually all staging systems.
Similar articles
-
Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.J Urol. 2008 Jan;179(1):163-6. doi: 10.1016/j.juro.2007.08.172. Epub 2007 Nov 14. J Urol. 2008. PMID: 18001800 Clinical Trial.
-
Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?Hematol Oncol Clin North Am. 2011 Jun;25(3):517-27,viii. doi: 10.1016/j.hoc.2011.03.013. Hematol Oncol Clin North Am. 2011. PMID: 21570606 Review.
-
Surgical aspects in the treatment of patients with testicular cancer.Hematol Oncol Clin North Am. 1991 Dec;5(6):1127-42. Hematol Oncol Clin North Am. 1991. PMID: 1663937 Review.
-
Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.Expert Rev Anticancer Ther. 2005 Feb;5(1):75-85. doi: 10.1586/14737140.5.1.75. Expert Rev Anticancer Ther. 2005. PMID: 15757440 Review.
-
Overview: treatment of local regional disease.Prog Clin Biol Res. 1990;350:283-93. Prog Clin Biol Res. 1990. PMID: 2166958 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical